Triple-Negative Breast Cancer
Also known as: Triple-Negative Breast Cancer (TNBC) / ER-Negative PR-Negative HER2-Negative Breast Cancer / TNBC / Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative / Triple negative breast cancer / Triple negative breast cancer metastatic / Triple negative malignant neoplasm of breast (disorder) / Triple Negative Breast Neoplasms
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB11595 | Atezolizumab | A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB11595 | Atezolizumab | Programmed cell death 1 ligand 1 | target |
| DB11595 | Atezolizumab | Programmed cell death protein 1 | target |